KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBITDA Margin (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of EBITDA Margin data on record, last reported at 90.33% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 9349.0% year-over-year to 90.33%; the TTM value through Dec 2025 reached 341.45%, down 14040.0%, while the annual FY2025 figure was 341.45%, 14040.0% down from the prior year.
  • EBITDA Margin reached 90.33% in Q4 2025 per PACB's latest filing, up from 98.47% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 47.51% in Q3 2021 and bottomed at 1146.92% in Q1 2025.
  • Average EBITDA Margin over 5 years is 224.0%, with a median of 171.98% recorded in 2023.
  • The widest YoY moves for EBITDA Margin: up 37614bps in 2025, down -94413bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 195.57% in 2021, then crashed by -55bps to 303.03% in 2022, then soared by 55bps to 137.02% in 2023, then skyrocketed by 102bps to 3.16% in 2024, then crashed by -2957bps to 90.33% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 90.33% in Q4 2025, 98.47% in Q3 2025, and 105.73% in Q2 2025.